Rodman & Renshaw Annual Global Investment Conference

September 11th - 13th, 2016

Lotte New York Palace Hotel, New York City

Rodman & Renshaw will host more than 200 public and private companies at the three-day 18th Annual Global Investment Conference in New York City. This year's conference will connect growth companies together with a vast audience of financial and strategic investors. The more than 2,000 attendees will enjoy access to corporate presentations from growth companies in the healthcare, natural resources, technology, media and telecommunications, cleantech and other industries; investor one-on-one meetings; keynote speakers; and daily networking opportunities over breakfast, lunch and cocktails. For more information on Rodman & Renshaw, visit

Conference Dates: A-M N-Z

Presenting Companies

Nabriva Therapeutics AG (NBRV)

Nabriva Therapeutics (NASDAQ: NBRV) is a clinical-stage biopharma company that researches and develops innovative antibiotics for severe infections. With a focus on pleuromutilin type of antibiotics, the company's main product is lefamulin, which has recently completed phase 2 clinical trials. Lefamulin was developed for the treatment of CABP (community-acquired bacterial pneumonia), though Nabriva is confident the drug can be tweaked so as to tackle other infections such as bacterial skin and skin structure infections. For more information, visit the company's website at

Nano Dimension Ltd. (NNDM)

Nano Dimension (NASDAQ: NNDM) is a technology company focused on the research and development of advanced 3D printed electronics. The company's offering includes a 3D printer for multilayer printed circuit boards, and the development of nanotechnology-based conductive and dielectric inks, which are complementary products for 3D printers. Its proprietary technologies enable the use of conductive and dielectric inks for ultra-rapid prototyping of complex, high-performance multilayer circuit boards. The company's PCB 3D printer is the result of combining advanced breakthroughs in inkjet technology, 3D printing and nanotechnology. For more information, visit the company's website at

NanoViricides, Inc. (NNVC)

NanoViricides (NYSE: NNVC) is a nano-biopharmaceutical company focused on discovering, developing, and marketing therapeutics for the treatment of viral infections. The company is developing anti-flu drug candidates at pre-clinical and advanced pre-clinical stage. These candidates include two FluCide drugs made up of NV-INF-2, an oral anti-influenza drug and NV-INF-1, an injectable anti-influenza drug for novel strain of H7N9, Bird Flu H5N1, and other Pathogenic Influenzas. For more information, visit the company's website at

NantKwest, Inc. (NK)

NantKwest (NASDAQ: NK) is a clinical-stage biotech company that develops novel immunotherapy agents based on their unique activated natural killer cell platform. The company's main product candidates, many of which are in phase 2 clinical trials, are designed for the treatment of various infectious and inflammatory diseases and cancer. NantKwest is developing therapies for ailments such as cervical, head and neck cancer, breast cancer, colorectal cancer, ebola, polyoma virus induced merkel cell carcinoma, non-hodgkin lymphoma. For more information, visit the company's website at

Nemus Bioscience, Inc. (NMUS)

Nemus Bioscience (OTC: NMUS) is a biopharma company that develops and markets cannabinoid-based treatments for various medical needs worldwide. Lead product candidates include glaucoma treatment NB1111 and NB1222, to treat nausea and vomiting caused by chemotherapy. Nemus is currently researching and developing other products for the treatment of staphylococcus aureus infections and peripheral neuropathy triggered by chemotherapy. The company uses a proprietary technology licensed from the University of Mississippi, with the aim of enhancing the effects of cannabinoid-based drugs without the potentially negative side effects. For more information, visit the company's website at

Nephros, Inc. (NEPH)

Nephros (OTC: NEPH) is a medical device company developing and commercializing liquid purification filters and hemodiafiltration systems for end-stage renal disease patients on dialysis. The company's ultrafilters are primarily used in dialysis centers for filtering out contaminants from water and bicarbonate concentrate typically used in the dialysis process. The filters have U.S. Federal Drug Administration clearance and are also used in clinics or hospitals to prevent water borne pathogen infections. Other uses include outdoor recreational, military or commercial. For more information, visit the company's website at

Neurometrix, Inc. (NURO)

Neurometrix (NASDAQ: NURO) is an innovative health-care company that develops wearable medical technology and point-of-care test that help patients and physicians better manage chronic pain, nerve diseases, and sleep disorders. The company's expertise in biomedical engineering has been refined over nearly two decades of designing, building and marketing medical devices that stimulate nerves and analyze nerve response for diagnostic and therapeutic purposes. NeuroMetrix created the market for point-of-care nerve testing and was first to market with sophisticated, wearable technology for management of chronic pain. For more information, visit the company's website at

NeuroVive Pharmaceutical AB (NEVPF)

NeuroVive Pharmaceutical AB (OTC: NEVPF) is a pharmaceutical company focused on mitochondrial research and development. The company works on producing drug candidates that protect the integrity of the mitochondria, and enhance their function in indications with pressing medical need. Two of NeuroVive's drug candidates, CicloMulsion® and NeuroSTAT®, are currently in early phase 2 trials. CicloMulsion® is being studied for preoperative treatment of acute kidney injury (AKI). The company also possesses two development platforms designed to develop drug candidates for treating ischemic stroke and a range of mitochondrial disorders. For more information, visit the company's website at

Newmarket Gold, Inc. (NMKTF)

Newmarket Gold (OTC: NMKTF) is a Canadian gold producer focused on operating within three 100% owned underground operating mines in Australia. The company's flagship operation, Fosterville Gold Mine, as well as the Stawell Gold Mine, are located in the state of Victoria; the Cosmo Gold Mine is located in the Northern Territory. Newmarket has a pipeline of growth projects within Australia, including The Maud Creek Gold Project in the Northern Territory and the Big Hill Gold Project in the state of Victoria. The company produces over 220,000 ounces of gold annually. For more information, visit the company's website at

Nicox SA (NICXF)

Nicox (OTC: NICXF) is an international commercial-stage ophthalmic company that focuses on the discovery and evaluation of effective therapies for late-stage ophthalmic ailments. The company's declared goal is that of building a diversified portfolio of products that address the complex needs of eye care patients and practitioners all over the world. Nicox is building its portfolio based on a proprietary nitric oxide based platform and in partnership with different leading biotech and pharmaceutical companies worldwide. The company's lead product candidates tackle ocular issues such as open angle glaucoma, hypertension or allergic conjunctivitis. For more information, visit the company's website at

NioCorp Developments Ltd. (NIOBF)

NioCorp Developments (OTC: NIOBF) is a U.S. company developing a superalloy materials project in Southeast Nebraska that will produce niobium, scandium, and titanium. Niobium is used to produce superalloys as well as High Strength, Low Alloy ("HSLA") steel, which is a lighter, stronger steel used in automotive, structural, and pipeline applications. Scandium is a superalloy material that can be combined with Aluminum to make alloys with increased strength and improved corrosion resistance. For more information, visit the company's website at

Nivalis Therapeutics, Inc. (NVLS)

Nivalis Therapeutics (NASDAQ: NVLS) is a clinical-stage pharmaceutical company focused on discovering, developing and marketing innovative therapeutics for people with cystic fibrosis (CF). The company's proprietary system, N91115 works through a novel mechanism of action called GSNOR inhibition, which is presumed to modulate the unstable and defective CFTR protein responsible for CF. GSNOR inhibition restores GSNO levels thereby modifying the chaperones responsible for CFTR protein degradation. Nivalis plans to utilize its proprietary GSNOR inhibitor portfolio to develop therapeutics for other diseases. For more information, visit the company's website at

NovaBay Pharmaceuticals, Inc. (NBY)

NovaBay Pharmaceuticals (NYSE: NBY) is a biopharmaceutical company focused on the commercialization of prescription Avenova® Lid and Lash Cleanser for the eye care market. Avenova is formulated with Neutrox™, which is cleared by the U.S. Food and Drug Administration (FDA) as a 510(k) medical device. Neutrox is NovaBay's pure hypochlorous acid. Avenova is marketed to optometrists and ophthalmologists throughout the United States. For more information, visit the company's website at

NovaCopper, Inc. (NCQ)

NovaCopper (NYSE: NCQ) is a metals exploration company focused on exploring and developing the Ambler mining district located in northwestern Alaska. The company's exploration efforts have been focused on two deposits in the Ambler district - the Arctic VMS deposit and the Bornite carbonate replacement deposit. NovaCopper has an agreement with NANA Regional Corporation, Inc., a Regional Alaska Native Corporation that provides a framework for the exploration and potential development of the Ambler mining district in cooperation with local communities. For more information, visit the company's website at

Novogen Ltd. (NVGN)

Novogen (NASDAQ: NVGN) is a specialty biotechnology company focused on developing oncology solutions. The company has two proprietary drug discovery platforms (superbenzopyrans and anti-tropomyosins) with the potential to yield first-in-class agents across a range of oncology indications. The three lead molecules - Cantrixil, Anisina and Trilexium - are in preclinical development, with the most advanced molecule, Cantrixil, slated to enter clinical trials in late 2016. For more information, visit the company's website at

Oculus Innovative Sciences, Inc. (OCLS)

Oculus Innovative Sciences (NASDAQ: OCLS) is global pharmaceutical company that specializes in the development of effective solutions for the treatment of dermatological conditions and advanced tissue care. The company's proprietary products have improved outcomes for more than 5 million patients globally by reducing infections, itch, pain, scarring and harmful inflammatory responses. The company's headquarters are in Petaluma, California, with manufacturing operations in the United States and Latin America. European marketing and sales are headquartered in Roermond, Netherlands. For more information, visit the company's website at

Oncolytics Biotech, Inc. (ONCYF)

Oncolytics Biotech (ONCYF) is a biopharmaceutical company developing oncolytic viruses for use as cancer therapeutics. The company's clinical program includes a variety of later-stage, randomized human trials in various indications using REOLYSIN®, its proprietary formulation of the human reovirus. REOLYSIN®, an acronym for Respiratory Enteric Orphan Virus, has been shown to be well-tolerated, with patients exhibiting only mild, flu-like symptoms. REOLYSIN® has been used alone and in combination with biologics, chemotherapy and radiotherapy for various cancers. For more information, visit the company's website at

Onconova Therapetuics, Inc. (ONTX)

Onconova Therapeutics (NASDAQ: ONTX) is a phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer. The company's clinical and pre-clinical stage drug development candidates are derived from its extensive chemical library and are designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. In addition to rigosertib, Onconova's most advanced product candidate, two other candidates are clinical stage, and several candidates are in pre-clinical stages. For more information, visit the company's website at

OncoSec Medical, Inc. (ONCS)

OncoSec Medical (NASDAQ: ONCS) is a biopharmaceutical company developing its investigational ImmunoPulse® intratumoral cancer immunotherapy. Clinical studies of ImmunoPulse® have demonstrated an acceptable safety profile and preliminary evidence of anti-tumor activity in the treatment of various skin cancers, as well as the potential to initiate a systemic immune response without the systemic toxicities associated with other treatments. OncoSec's lead program evaluating ImmunoPulse® for the treatment of metastatic melanoma is currently in phase 2 development, and is being conducted in collaboration with several prominent academic medical centers. For more information, visit the company's website at

Opexa Therapeutics, Inc. (OPXA)

Opexa Therapeutics (NASDAQ: OPXA) is a biopharmaceutical company developing personalized immunotherapies with the potential to treat major illnesses such as multiple sclerosis (MS) and autoimmune diseases like neuromyelitis optica (NMO). These treatments are based on Opexa's proprietary T-cell technology. The company's leading therapy candidate, Tcelna®, is a personalized T-cell immunotherapy that is in a phase 2b clinical development program (the Abili-T trial) for the treatment of secondary progressive MS. For more information, visit the company's website at

OpGen, Inc. (OPGN)

OpGen (NASDAQ: OPGN) is a biopharmaceutical company focusing on providing healthcare professionals with the tools to combat antibiotic-resistant infections by using molecular diagnostics and bioinformatics technologies. The company's CLIA- certified laboratory helps affordably screen for, prevent and diagnose MDRO threats. OpGen's flagship test is Acuitas® MDRO Gene Test that directly detects 10 genes unique to critical multi-drug resistant organisms (MDRO). Detection includes genes associated with Gram-negative carbapenem-resistant enterobacteriaceae (CRE). For more information, visit the company's website at

Opiant Pharmaceuticals, Inc. (OPNT)

Opiant Pharmaceuticals (OTC: OPNT) is a specialty pharmaceutical company developing innovative therapies for addictive eating disorders and substance use problems. With its innovative opioid antagonist nasal delivery technology, the company's first product, NARCAN® Nasal Spray, is approved for marketing in the U.S. by the company's partner, Adapt Pharma Limited. Currently, Opiant is developing opioid antagonists for the treatment of substance use, addictive and eating disorders, with a near-term focus on cocaine use disorder and binge eating disorder (BED). For more information, visit the company's website at

Oramed Pharmaceuticals, Inc. (ORMP)

Oramed Pharmaceuticals (NASDAQ: ORMP) is a pharmaceutical company striving to become a technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Using its Protein Oral Delivery (PODTM) technology, Oramed seeks to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801). The company completed multiple phase 2 clinical trials under an Investigational New Drug application with the U.S. Food and Drug Administration. In addition, Oramed is developing an oral GLP-1 analog capsule (ORMD-0901). For more information, visit the company's website at

Orexigen Therapeutics, Inc. (OREX)

Orexigen Therapeutics (NASDAQ: OREX) is a biopharmaceutical company focused on finding innovative solutions for the treatment of obesity. Orexigen's first medicine, Contrave® (naltrexone HCl and bupropion HCl extended release), was approved in the United States in September 2014 and has become the most prescribed branded obesity medication since June 2015. The product is indicated for use as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition. For more information, visit the company's website at

Orion Energy Systems, Inc. (OESX)

Orion Energy Systems (NASDAQ: OESX) is a manufacturer and designer of high-performance retrofit lighting systems for commercial offices and retail areas, industrial buildings, or exterior areas across North America. The company manufactures and provides energy-efficient, state-of-the-art lighting systems and retrofit lighting solutions, and has a portfolio of high-intensity fluorescent lighting and LED solid-state lighting. Orion also offers various smart building control systems that include lighting control, as well as energy management services. In addition, it has 100+ granted patents and pending patent applications relating to lighting systems with excellent thermal and optical performance. For more information, visit the company's website at

OSE Immunotherapeutics (ORPHF)

OSE Immunotherapeutics (OTC: ORPHF is a biotechnology company specializing in immune regulation with clinical applications in immuno-oncology, autoimmune diseases and transplantation. The company has several advanced immunotherapy products in clinical phase 3 and in phase 2 with Tedopi® (combined neoepitopes in oncology, developed in advanced lung cancer, NSCLC); and FR104 in phase 1. For more information, visit the company's website at

OvaScience, Inc. (OVAS)

OvaScience (NASDAQ: OVAS) is a global fertility company dedicated to improving treatment options for women, and developing and commercializing new fertility treatments. The company's flagship product is based on its proprietary technology platform that leverages the breakthrough discovery of egg precursor (EggPCSM) cells – immature egg cells found inside the protective ovarian lining. The AUGMENTSM treatment, a fertility option specifically designed to improve egg health, is available in certain IVF clinics in select international regions outside of the United States. The company also develops a potential next-generation IVF treatment that could help a woman produce healthy, young, fertilizable eggs without hormone injections. For more information, visit the company's website at

Oxford BioMedica PLC (OXBDF)

Oxford BioMedica (OTC: OXBDF) is focused on using cell and gene therapy to develop life changing treatments for serious diseases. The company's platform of exclusive cutting-edge technologies and capabilities LentiVector® focuses on the areas of oncology, ophthalmology and CNS disorders. Oxford BioMedica has a broader interest in multiple partnered royalty-bearing product candidates with Novartis, GSK, Sanofi and Immune Design. For more information, visit the company's website at

Oxis International, Inc. (OXIS)

Oxis International (OTQCB: OXIS) is a pharmaceutical company that develops innovative drugs focused on the treatment of cancer. The company's lead drug candidate, OXS-1550 (DT2219ARL), is a novel bispecific scFv recombinant fusion protein-drug conjugate that simultaneously targets cancer cells expressing the CD19 receptor or CD22 receptor or both receptors. The product has demonstrated success in early human clinical trials in patients with relapsed/refractory B-cell lymphoma or leukemia. For more information, visit the company's website at

Pacific Ethanol, Inc. (PEIX)

Pacific Ethanol (NASDAQ: PEIX) is a producer and provider of low-carbon renewable fuels in Western United States. Based in Sacramento, California, the company runs eight ethanol production facilities: four in California, Idaho and Oregon and four in Nebraska and Illinois, with a combined production capacity of 515 million gallons of ethanol a year and over 1 million tons of ethanol co-products including condensed distiller's solubles, wet and dry corn gluten feed, corn germs, corn gluten meals, distiller's yeasts and grains, and CO2. Pacific Ethanol also provides ethanol storage, transportation and delivery services. For more information, visit the company's website at

Paion AG (PAIOF)

Paion AG (OTC: PAIOF) is a global pharmaceutical company specialized in finding innovative solutions for the sedatives/ anesthetic field. The company's flagship product, Remimazolam, is an intravenous ultra-short-acting benzodiazepine sedative/anesthetic currently in phase 3 clinical development for procedural sedation. PAION is focusing its clinical development activities on Remimazolam according to PAION's vision to become an acknowledged "PAIONeer" in sedation and anesthesia. The company has headquarters in Aachen (Germany) with subsidiaries in Cambridge (United Kingdom) and New Jersey (USA). For more information, visit the company's website at

Paramount Gold Nevada Corp. (PZG)

Paramount Gold Nevada (NYSE: PZG) is a U.S.-based precious metals exploration company. Its main strategy is to create shareholder value through the exploration and development of U.S. properties and then selling to, or entering into joint ventures with, producers for construction and operation. Paramount owns a 100% interest in the Sleeper Gold Project located in Northern Nevada. The Sleeper Gold Project, which includes the former producing Sleeper high-grade gold mine, totals 2,322 unpatented mining claims (approximately 60 square miles or 15,500 hectares). For more information, visit the company's website at

PAVmed, Inc. (PAVM)

PAVmed (NASDAQ: PAVM) is a multi-product medical device company that focuses on advancing products from concept to commercialization much more rapidly and with significantly less capital than the typical medical device company. This proprietary model enables PAVmed to pursue an expanding multi-product pipeline strategy with a view to enhancing and accelerating value creation. PAVmed's diversified pipeline of products various clinical areas including carpal tunnel syndrome (CarpX™), medical infusions (NextFlo™ and NextCath™), interventional radiology (PortIO™ and NextCath), tissue ablation and cardiovascular intervention (Caldus™). For more information, visit the company's website at

Perion Network Ltd. (TASE)

Perion Network (NASDAQ: TASE) is a global technology company that delivers high-quality advertising solutions to brands and publishers. The company's digital ad platform, Undertone, provides brands with standout, high-impact cross-screen creative that captures consumer attention and drives engagement. Its social and mobile platform, Growmobile, offers marketers an unmatched solution for acquiring and engaging app users, while its Codefuel provides publishers with engagement and monetization solutions, using high-quality ad formats and search results. For more information, visit the company's website at

Pershing Gold Corp. (PGLC)

Pershing Gold (NASDAQ: PGLC) is a Nevada-based gold producing company uniquely positioned for mining operations in the Relief Canyon Mine. Pershing Gold's strategy to create shareholder value is based on advancing the whole area to commercial production. The Relief Canyon Mine property includes three open-pit mines and a state-of-the-art, fully constructed heap leach processing facility. The plant has the capacity to process gold bearing solutions from the leaching of 8 million tons of ore per year. For more information, visit the company's website at

Pieris Pharmaceuticals, Inc. (PIRS)

Pieris Pharmaceuticals (NASDAQ: PIRS) is a clinical-stage biotech company that focuses on the development of Anticalin-based drugs to target validated disease pathways in a unique and transformative way. The company's pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment; an inhaled Anticalin to treat uncontrolled asthma; and a half-life-optimized Anticalin to treat anemia. Proprietary to the company, Anticalins are a novel class of protein therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. For more information, visit the company's website at

Plug Power, Inc. (PLUG)

Plug Power (NASDAQ: PLUG) is a provider of alternative energy technology that designs, develops, manufactures and sells fuel cell systems. The company's main products are based on the revolutionary GenKey solution, designed to lower operating costs, increase productivity and reduce carbon footprints for the U.S. material handling and stationary power market. Products range from hydrogen fueling delivery systems to fuel cell maintenance products, fuel cell solutions for telecommunications, utility and transportation sectors. Plug Power focuses on proton exchange membrane fuel cell technologies and battery/fuel cell hybrid technologies. For more information, visit the company's website at

Pointer Telocation Ltd. (PNTR)

Pointer Telocation (NASDAQ: PNTR) provides technology and services to the automotive and insurance industries. The company, based in Israel, is offering a set of services including mobile resource management, fleet management and stolen vehicle recovery. Cellocator, a Pointer Products Division, is a leading AVL (Automatic Vehicle Location) solutions provider for stolen vehicle retrieval, fleet management, car & driver safety, public safety, vehicle security and more. For more information, visit the company's website at

PolyMet Mining Corp. (PLM)

PolyMet Mining (NYSE: PLM) is a mine development company that owns 100 percent of Poly Met Mining, Inc., a Minnesota corporation that controls the NorthMet copper-nickel-precious metals ore body through a long-term lease and owns the Erie Plant, a large processing facility located approximately six miles from the ore body in the established mining district of the Mesabi Iron Range in northeastern Minnesota. For more information, visit the company's website at

Presbia PLC (LENS)

Presbia (NASDAQ: LENS) is a medical device company focused on the development of the presbyopia-correcting products. The company's main solution is Presbia Flexivue Microlens™ – an innovative solution for the common age-related loss of the ability to read or focus on near objects. The 3mm diameter lens is implanted in a corneal pocket created by a femtosecond laser. The Presbia Flexivue Microlens™ is currently commercialized across the U.S. and Europe. For more information, visit the company's website at

Probiodrug AG (PRBGF)

Probiodrug AG (NASDAQ: PRBGF) is a German-based biopharmaceutical company focused on the development of innovative small molecule drugs for the treatment of neuronal, inflammatory and autoimmune diseases. The company has a dominant position in the area of glutaminyl cyclase (QC) inhibition, an enzyme central for the pathogenesis of Alzheimer's disease (AD). In this field, Probiodrug is pioneering a completely novel therapeutic approach. In addition, the company is pursuing further novel approaches in the area of inflammatory diseases. For more information, visit the company's website at

ProMIS Neurosciences, Inc. (ARFXF)

ProMIS Neurosciences (OTC: ARFXF) is a pharmaceutical research company focused on developing precision medicine therapeutics for the effective treatment of neurodegenerative diseases, in particular Alzheimer's disease and ALS. The company uses its computational discovery platform, ProMIS™, to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. In addition, ProMIS Neurosciences owns the exclusive rights to the genus patent relating to misfolded SOD1 in ALS, and currently has a preclinical monoclonal antibody therapeutic against this target. For more information, visit the company's website at

Propanc Health Group Corp. (PPCH)

Propanc Health Group (OTC: PPCH) is a development-stage healthcare company that focuses on producing new cancer treatments and solutions for patients suffering from pancreatic and colorectal cancer. The company has developed a rational, composite formulation of anti-cancer compounds designed to control or prevent tumors from recurring and spreading through the body. Propanc's products are variations upon their novel formulation and involve or employ proenzymes, which are inactive precursors of enzymes. For more information, visit the company's website at

Protalix BioTherapeutics, Inc. (PLX)

Protalix BioTherapeutics (NYSE: PLX) is a biopharmaceutical company that focuses on developing and marketing recombinant therapeutic proteins through its ProCellEx® plant cell-based protein expression system. Using ProCellEx, the company is developing a proprietary pipeline of best-in-class versions of recombinant therapeutic proteins. Having successfully developed ELELYSO™ (taliglucerase alfa for injection), the company intends to develop additional proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications. For more information, visit the company's website at

Proteon Therapeutics, Inc. (PRTO)

Proteon Therapeutics (NASDAQ: PRTO) is a late-stage biopharmaceutical company that focuses on developing first-in-class therapies for patients with kidney and vascular diseases. The company's flagship clinical stage product is Vonapanitase, an investigational drug designed to treat vessel injury that leads to blockages in blood vessels and reduced blood flow. The product is currently in two stage 2 and stage 3 developments for CKD patients in hemodialysis and undergoing radiocephalic arteriovenous fistula (RC AVF) surgery. For more information, visit the company website at

Provectus Biopharmaceuticals, Inc. (PVCT)

Provectus Biopharmaceuticals (NYSE: PVCT) specializes in developing oncology and dermatology therapies. PV-10, the company's novel investigational drug for cancer, is designed for injection into solid tumors, thereby reducing potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and cancers of the liver. Provectus has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. PH-10, its topical investigational drug for dermatology, is undergoing clinical testing for psoriasis and atopic dermatitis. Provectus has completed phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and psoriasis. For more information, visit the company's website at

Pulmatrix, Inc. (PULM)

Pulmatrix (NASDAQ: PULM) is developing innovative inhaled therapies to address serious pulmonary disease using its clinically validated, proprietary iSPERSE technology. Leveraging the unique capabilities of iSPERSE to dramatically advance inhalation technology, the company means to create new therapies to improve patient outcomes. Pulmatrix's pipeline of inhaled therapies represents innovative, first-in-class products. This proprietary pipeline of novel, therapies for rare, orphan diseases is led by PUR1900, an inhaled anti-infective to treat fungal infections in cystic fibrosis or immune compromised patients. For more information, visit the company's website at

PURE Bioscience, Inc. (PURE)

PURE Bioscience (OTC: PURE) is a biopharmaceutical company currently developing and revolutionary antimicrobial solutions to the health and environmental challenges of pathogen and hygienic control. The company's technology platform is based on patented, stabilized ionic silver, and its initial products contain Silver Dihydrogen Citrate (SDC). SDC is a broad-spectrum, non-toxic antimicrobial agent that is manufactured as a liquid and delivered in various concentrations. PURE currently manufactures SDC-based disinfecting and sanitizing products, which are registered by the United States Environmental Protection Agency (EPA). For more information, visit the company website at

Radius Health, Inc. (RDUS)

Radius Health (NASDAQ: RDUS) is a revolutionary biopharmaceutical company committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The company's flagship product candidate, the investigational drug Abaloparatide for subcutaneous injection, has completed phase 3 development for potential use in the reduction of fracture risk in postmenopausal women with osteoporosis. The company also has several associated products in the pipeline: the investigational Abaloparatide transdermal patch for potential use in osteoporosis; the investigational drug RAD1901 for potential use in hormone-driven and/or hormone-resistant breast cancer; and vasomotor symptoms in postmenopausal women. For more information, visit the company's website at

Recro Pharma, Inc. (REPH)

Recro Pharma (NASDAQ: REPH) is a pharmaceutical company specialized in developing non-opioid products for the treatment of acute pain. The company's main candidate is a proprietary injectable form of meloxicam. Intravenous (IV) meloxicam has successfully completed multiple phase 2 clinical trials for the treatment of moderate to severe pain. Recro's pipeline also includes Dex-IN, a proprietary intranasal formulation of dexmedetomidine (Dex), which successfully completed a phase 2 clinical trial in post-operative pain. The company's flagship products are non-addictive, non-opioid drugs. For more information, visit the company website at

RedHill Biopharma Ltd. (RDHL)

RedHill Biopharma Ltd. (NASDAQ: RDHL) is an Israeli biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage drugs for the treatment of inflammatory and gastrointestinal diseases, including cancer. The company is working to develop proprietary, orally administered, small molecule drugs. RedHill's current pipeline of proprietary products includes RHB-105, an oral combination therapy for Helicobacter pylori infection, which has completed the first phase 3 study. For more information, visit the company's website at

Regenerx Biopharmaceuticals, Inc. (RGRX)

Regenerx Biopharmaceuticals (OTC: RGRX) is a clinical-stage biopharmaceutical company focused on tissue protection, repair and regeneration. The company is moving three distinct Tβ4-based drug candidates through the clinic: RGN-137, RGN-259 and RGN-352. RegeneRx also holds over 75 issued patents or patent applications worldwide in order to enable and protect multiple indications and applications for its product candidates. For more information, visit the company's website at

Relmada Therapeutics, Inc. (RLMD)

Relmada Therapeutics, Inc. (OTC: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of pain. The Company has four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain. The company's goal is to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs. For more information, visit the company's website at

Repros Therapeutics, Inc. (RPRX)

Repros Therapeutics (NASDAQ: RPRX) is a development-stage biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The company's flagship product, Enclomiphene, ia for men of reproductive age with low testosterone due to secondary hypogonadism. Another leading product currently in development is Proellex, a new chemical entity that acts as a selective blocker of the progesterone receptor and is being developed for the treatment of symptoms associated with uterine fibroids and endometriosis. For more information, visit the company's website at

Resonant, Inc. (RESN)

Resonant (NASDAQ: RESN) is a technology company focused on creating innovative filter designs for the RF front-end (RFFE) for the mobile device industry. The company's large suite of proprietary mathematical methods, software design tools and network synthesis techniques enable it to explore a much bigger set of possible solutions and quickly derive the better ones. These improved filters still use existing manufacturing methods (i.e. SAW) and can perform as well as those using higher cost methods (i.e. BAW). For more information, visit the company's website at

RespireRx Pharmaceuticals, Inc. (RSPI)

RespireRx Pharmaceuticals (OTC: RSPI) is a groundbreaking pharmaceutical company focused on finding efficient solutions for breathing disorders. The company has two key clinical development areas. The first is focused on finding therapies for sleep apnea. The resulting product, Dronabinol, has shown the ability to reduce the apnea-hypopnea index (AHI), an hourly sleep apnea score, in patients with moderate-severe OSA. A second key program develops positive allosteric modulators of the AMPA-type glutamate receptor (PAM-A compounds) which can prevent or alleviate respiratory depression, a potentially lethal side effect of opiate analgesics or anesthetic agents. For more information, visit the company's website at

Resverlogix Corp. (RVXCF)

Resverlogix (OTC: RVXCF) is developing apabetalone (RVX-208), a first-in-class, small molecule selective BET bromodomain inhibitor, the only selective BET bromodomain inhibitor in clinical trials. BET bromodomain inhibition can turn disease-causing genes off, returning them to a healthier state. Apabetalone is the first and only BET inhibitor selective for BRD4-BD2, with potentially important benefits for patients with diseases such as cardiovascular disease, diabetes mellitus, chronic kidney disease, peripheral artery disease, Orphan diseases (PNH), and Alzheimer's disease. Resverlogix has commenced a phase 3 clinical trial in CVD patients with a primary endpoint of time to first occurrence of Major Adverse Cardiac Events (MACE). For more information, visit the company's website at

Revolution Lighting Technologies, Inc. (RVLT)

Revolution Lighting Technologies (NASDAQ: RVLT) is a designer and manufacturer of LED lighting solutions for industrial, commercial and government markets in the U.S., Canada and globally. The company offers innovative, high-quality exterior and interior LED fixtures and lamps, including control systems and signage, under the Seesmart brand. It also provides a patented smart grid control system for various outdoor lighting applications. The company distributes its products through a network of independent distributors and sales representatives, but also through national accounts and energy savings companies. For more information, visit the company's website at

Rexahn Pharmaceuticals, Inc. (RNN)

Rexahn Pharmaceuticals (NYSE: RNN) is a clinical-stage biopharmaceutical company focused on developing best-in-class therapeutics for the treatment of cancer. The company's clinical development programs directly target specific proteins that are selectively expressed in human cancer cells, resulting in increased efficacy and reduced toxicity. In preclinical studies these drug candidates are effective against multiple drug resistant cancers and have shown to increase the effectiveness of various FDA approved cancer treatments. Rexahn is also developing specific biomarker tests that will help identify which patients will be most responsive to its treatments. For more information, visit the company's website at

Sandstorm Gold Ltd. (SAND)

Sandstorm Gold (NYSE: SAND) is a financial company that provides financing to gold mining companies through gold stream and royalty agreements. Stream and royalty finance involves the company making an upfront payment to a mining partner that is in need of capital to build their mine, refinance their obligations, complete an acquisition or for various other reasons. In exchange for that upfront payment, Sandstorm receives the right to purchase a percentage of the gold produced from the mine. For more information, visit the company's website at

SciClone Pharmaceuticals, Inc. (SCLN)

SciClone Pharmaceuticals (NASDAQ: SCLN) is a specialty pharmaceutical company focused on several major therapeutic markets including oncology, infectious diseases, and cardiovascular disorders. The company's proprietary lead product, ZADAXIN® (thymalfasin), may be used for the treatment of hepatitis B (HBV), hepatitis C (HCV), and certain cancers, and as an immune system enhancer. SciClone has successfully in-licensed and commercialized products including DC Bead®, a novel treatment for liver cancer, now approved in China, and several other products in late-stage development in China. For more information, visit the company's website at

Second Sight Medical Products, Inc. (EYES)

Second Sight Medical Products (NASDAQ: EYES) is a medical company with a mission to develop, manufacture and market innovative implantable visual prosthetics to enable blind individuals to achieve greater independence. The company is in marketing stage with Argus® II Retinal Prosthesis System. Enrollment for the product has been completed in a trial to test the safety and utility of the Argus II in individuals with Dry Age-Related Macular Degeneration. Second Sight is also developing the Orion™ I Visual Cortical Prosthesis to restore some vision to individuals who are blind due to causes other than preventable or treatable conditions. For more information, visit the company's website at

Senomyx, Inc. (SNMX)

Senomyx (NASDAQ: SNMX) is a researcher and manufacturer of novel flavor ingredients and natural high intensity sweeteners that allow food and beverage companies to create healthier products. Under its direct sales program, the company sells its Complimyx® brand flavor ingredients - Sweetmyx®, Savorymyx®, and Bittermyx® - to flavor companies for use in a wide variety of foods and beverages. In addition, Senomyx has partnerships with leading global food, beverage, and ingredient supply companies, which are currently marketing products that contain Senomyx's flavor ingredients. For more information, visit the company's website at

Sierra Metals, Inc. (DBEXF)

Sierra Metals (OTC: DBEXF) is a premier Latin American precious and base metals producer. The company owns and operates three mines in commercial production: the Yauricocha Mine in Peru, and the Bolivar and Cusi mines in Mexico. Currently, extensive exploration and development programs are underway to increase known reserves and resources within close proximity to each mine. Additionally, broader regional targets are being explored to continue advancing the company's project pipeline toward production. For more information, visit the company's website at

Signal Genetics, Inc. (SGNL)

Signal Genetics (NASDAQ: SGNL) is a commercial-stage molecular diagnostics company that provides improved diagnostic solutions for cancer treatment. The company was founded in April 2010 after becoming the exclusive licensee to the world-renowned research on multiple myeloma performed at the University of Arkansas for Medical Sciences (UAMS). More than 30 years of clinical research on nearly 10,000 multiple myeloma patients who received their care at UAMS (Myeloma Prognostic Risk Signature). Signal Genetics offers the MyPRS test out of its state-of-the-art, CLIA-certified reference laboratory located in Little Rock, Arkansas. For more information, visit the company's website at

Smith Micro Software, Inc. (SMSI)

Smith Micro Software (NASDAQ: SMSI) is a U.S.-based developer and marketer of both enterprise and consumer-level software and services. Based in Aliso Viejo, California, Smith Micro maintains multiple domestic and international offices throughout the U.S, in Asia and Europe. Its innovative wireless solutions improve the quality of experience for mobile users through connectivity optimization, policy-on-device control and analytics-driven insights. These solutions also enable enterprises, brands and communication service providers to engage with their subscribers in personalized, more valuable ways. For more information, visit the company's website at

Social Reality, Inc. (SCRI)

Social Reality (OTCQB: SCRI) is an Internet advertising company focused on providing the tools that automate the digital advertising market. The company has built technologies and leveraged partner technologies that service social media and real-time bidding (RTB) markets. Social Reality's platforms connect online publishers with demand partners and buyers, provide targeted and measurable Facebook advertising campaigns and offer brand advocacy and customer loyalty campaigns, all through its proprietary technology. For more information, visit the company's website at

Solitario Exploration & Royalty Corp. (XPL)

Solitario Exploration & Royalty (NYSE: XPL) is a precious and base metal exploration and royalty company. The company currently focuses on financing and constructing the Mt. Hamilton gold project in Nevada. Solitario controls an 80% interest in Mt. Hamilton. The company has several collaboration ventures with several companies, among which a joint venture with Anglo Platinum on its Pedra Branca platinum-palladium project in Brazil. For more information, visit the company's website at

Sorrento Therapeutics, Inc. (SRNE)

Sorrento Therapeutics, Inc. (NASDAQ: SRNE) is a clinical-stage biopharmaceutical company developing new treatments for cancer, as well as associated pain, inflammation and immune diseases. The company recently licensed multiple late-stage biosimilar and biobetter antibodies for oncology and inflammation diseases in the U.S., European and Japanese markets. Sorrento's lead product is resiniferatoxin, a non-opiate TRPV1 agonist currently being developed as a treatment for terminal cancer patients suffering from intractable pain. For more information, visit the company's website at

Spectral Medical, Inc. (EDTXF)

Spectral Medical (OTC: EDTXF) is a Canadian company committed to decreasing the unacceptably high mortality rates caused by sepsis. As a leader in the area of endotoxin and its role in sepsis, the company is currently conducting a phase 3 clinical trial for its lead product, Toraymyxin, for the treatment of patients with septic shock. Toraymyxin is a therapeutic hemoperfusion device that removes circulating endotoxin from the bloodstream, which may result in a significant reduction in mortality. This is the first time that a theranostic approach, the combination of a diagnostic followed by a targeted therapy, will be used in the area of clinical trials for sepsis. For more information, visit the company's website at

Spectrum Pharmaceuticals, Inc. (SPPI)

Spectrum Pharmaceuticals (NASDAQ: SPPI) is a biotechnology company that creates and markets drug products with a primary focus in hematology and oncology therapies. The company currently markets six hematology/oncology drugs, and expects an FDA decision on another drug in the second half of 2016. Three of the clinical stage therapies are for different types of non-Hodgkins lymphoma, one for advanced metastatic colorectal cancer, one for a certain type of acute lymphoblastic leukemia (ALL) and one for multiple myeloma. There are two products in late-stage development, as well as a broad and diversified portfolio of proprietary drugs in various stages of development. For more information, visit the company's website at

Spring Bank Pharmaceuticals, Inc. (SBPH)

Spring Bank Pharmaceuticals (NASDAQ: SBPH) is a clinical-stage biopharmaceutical company developing a novel class of therapeutics using a proprietary small molecule nucleic acid hybrid, or SMNH, chemistry platform. The company is developing its most advanced SMNH product candidate, SB 9200, for the treatment of viral diseases. SB 9200 selectively activates within infected cells the cellular proteins retinoic acid-inducible gene 1, or RIG-I, and nucleotide-binding oligomerization domain-containing protein 2, or NOD2, to inhibit viral replication and to cause the induction of intracellular interferon signaling pathways for antiviral defense. For more information, visit the company's website at

SQI Diagnostics, Inc. (SQIDF)

SQI Diagnostics (OTC: SQIDF) is a diagnostics company that develops the most advanced multiplexed tests and automated systems for measuring a wide variety of biomarkers in blood or other common sample types. Multiplexed tests detect multiple analytes from a single biological specimen, the company has found a way to do this in an automated fashion. The SQI tests cover the testing needs for three markets: human diagnostics, animal health diagnostics, biotechnology drug development. For more information, visit the company's website at

Staffing 360 Solutions, Inc. (STAF)

Staffing 360 Solutions (NASDAQ: STAF) is a major international staffing company with diversified staffing services. Based on its growth buy-and-build model, the company has developed a significant pipeline of acquisition targets in the finance and accounting, administrative, engineering and IT industries. For more information, visit the company's website at

SteadyMed Ltd. (STDY)

SteadyMed (NASDAQ: STDY) is a specialized pharmaceutical company developing innovative solutions for the delivery of biologic drugs in various therapies. The company leverages its PatchPump platform to develop its own therapeutic portfolio to optimize the delivery of high volume, high value, small molecule or biologic drugs. Its proprietary PatchPumps can be customized to deliver liquid drugs, including biologics, with a wide range of volumes and viscosities, in a consistent and controllable manner. For more information, visit the company's website at

Stellar Biotechnologies, Inc. (SBOT)

Stellar Biotechnologies (OTCQB: SBOT) is the leading manufacturer of sustainable keyhole limpet hemocyanin (KLH), an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. Through a recently executed strategic collaboration, the company has established itself as the only KLH supplier with a reliable and scalable source of this vital nutrient. By leveraging its portfolio of proprietary harvesting methods and technologies, the company is committed to meeting the rapidly expanding demand for commercial-scale supplies of GMP-grade KLH. For more information, visit the company's website at

Stemline Therapeutics, Inc. (STML)

Stemline Therapeutics (NASDAQ: STML) is s a clinical-stage biopharmaceutical company developing novel therapeutics that target cancer stem cells (CSCs) and tumor bulk. Its two clinical stage product candidates are SL-401 and SL-701, and a pipeline of preclinical candidates that includes SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) present on CSCs and tumor bulk of a wide range of hematologic cancers. SL-701 is an immunotherapy designed to activate the immune system to attack tumors, and is being developed in adult patients with glioblastoma multiforme (GBM) in first recurrence. For more information, visit the company's website at

Sucampo Pharmaceuticals, Inc. (SCMP)

Sucampo Pharmaceuticals (NASDAQ: SCMP) is a biopharmaceutical company focused on the development and commercialization of medicines that meet major unmet medical needs of patients and medical experts. The company's flagship product is AMITIZA, a biprostone compound for treatment of chronic constipation, chronic idiopathic constipation (CIC) in adults, irritable bowel syndrome with constipation (IBS-C) in adult women and opioid-induced constipation (OIC) in adults with chronic non-cancer pain. A global company, Sucampo has operations in Japan, Switzerland and the U.K. For more information, visit the company's website at

Summit Therapeutics plc (SMMT)

Summit Therapeutics (NASDAQ: SMMT) is an international biopharmaceutical company that focuses on developing novel therapies for the treatment of the fatal muscle wasting disease Duchenne muscular dystrophy and infections caused by the bacteria C. difficile. The company's goal is to become a fully integrated biopharmaceutical provider of solutions for indications that currently have no existing or only inadequate therapies. For more information, visit the company's website at

Sunesis Pharmaceuticals, Inc. (SNSS)

Sunesis Pharmaceuticals (NASDAQ: SNSS) is a biopharmaceutical company specialized in the development and marketing of new oncology therapeutics for the potential treatment of solid and hematologic cancers. The company's most advanced program is QINPREZO™ (vosaroxin), a clinical stage candidate for the potential treatment of acute myeloid leukemia (AML). Vosaroxin is an anticancer quinolone derivative, or AQD—a class of compounds that has not been used previously for the treatment of cancer. For more information, visit the company's website at

Superconductor Technologies, Inc. (SCON)

Superconductor Technologies (NASDAQ: SCON) is a veteran company focused on pioneering the development of superconducting materials and manufacturing processes. Over the last decade, the company has manufactured and sold over 6,000 superconducting systems that have been deployed in tier-one wireless networks, thereby providing commercial deployments of its superconducting technology. STI is applying its proprietary superconducting deposition techniques and manufacturing experience to the development of cost effective, high-performance superconducting wire for emerging large market opportunities with electric utilities and smart grid applications. For more information, visit the company's website at

Syndax Pharmaceuticals, Inc. (SNDX)

Syndax Pharmaceuticals (NASDAQ: SNDX) is a biopharmaceutical company currently developing an innovative pipeline of combination therapies in multiple cancer indications. The company's flagship product candidate, Entinostat, was granted Breakthrough Therapy designation by the U.S. Food and Drug Administration following positive results from a phase 2b clinical trial. Another revolutionary product, ENCORE 301, is currently being evaluated in a phase 3 clinical trial for advanced hormone receptor positive breast cancer, and as a combination therapeutic in phase 1b/2 clinical trials for non-small cell lung cancer and melanoma. For more information, visit the company's website at

Synergy Pharmaceuticals, Inc. (SGYP)

Synergy Pharmaceuticals (NASDAQ: SGYP) is a New York-based biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies. The company's proprietary technology platform is based on uroguanylin, a naturally occurring human GI peptide, and includes two lead product candidates – Plecanatide and Dolcanatide. Plecanatide is the company's first uroguanylin analog currently being evaluated for use as a once-daily tablet for chronic idiopathic constipation and irritable bowel syndrome with constipation. Dolcanatide is being tested for ulcerative colitis. For more information, visit the company's website at

TearLab Corp. (TEAR)

TearLab (NASDAQ: TEAR) is a medical research company that develops and markets lab-on-a-chip technologies improving eye care diagnostics. The company markets a tear testing platform, the TearLab Osmolarity System, which enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. Through its subsidiary TearLab Research, Inc., TearLab develops technologies to test a range of biomarkers (chemistries, metabolites, genes and proteins) at the point-of-care. For more information, visit the company's website at

Tecogen, Inc. (TGEN)

Tecogen (NASDAQ: TGEN) is a next-generation manufacturer of natural-gas-fueled, engine-driven, combined heat and power (CHP) products. The company aims to reduce energy costs, reduce greenhouse gas emissions, and alleviate congestion on the national power grid. Tecogen's leading generation products include cogeneration modules, which provide electricity and heat, and chillers, which provide air-conditioning and optional free hot water. They also supply electrical power or mechanical power for cooling, as well as free engine heat that gets recovered and purposefully used at customer facilities. For more information, visit the company's website at

Theralase Technologies, Inc. (TLTFF)

Theralase Technologies (OTC: TLTFF) is a biopharmaceutical company that develops and manufactures super-pulsed cold laser technology for a wide range of human, companion animal and equine applications. The company's laser systems have biostimulative capabilities, including healing neural muscular skeletal conditions through pain elimination, inflammation reduction and increased tissue regeneration. Combining Theralase laser technology with photodynamic compounds (PDCs) leads to bio-destructive capabilities, including destruction of cancer cells, bacteria, viruses and fat cells. Theralase lasers penetrate deeper - up to 10 cm (4 in) below the skin surface - and heal tissue faster than any other cold laser on the market. For more information, visit the company's website at

Therapix Biosciences Ltd (THXBY)

Therapix Biosciences (OTC: THXBY) is a biopharmaceutical company that develops a line of groundbreaking therapies such as prescribed cannabinoid drugs and novel delivery systems. The company focuses on central nervous system (CNS) disorders with two leading indications: prevention of cognitive deterioration, such as Alzheimer's disease and movement disorders, such as Tourette (orphan indication). For more information, visit the company's website at

Tobira Therapeutics, Inc. (TBRA)

Tobira Therapeutics (NASDAQ: TBRA) is a clinical-stage biopharmaceutical company developing therapies to treat non-alcoholic steatohepatitis (NASH) and other liver diseases, inflammation, fibrosis and HIV. The company's main clinical candidates are Cenicriviroc (CVC), a first-in-class immunomodulator and dual inhibitor of CCR2; and CCR5 for the treatment of NASH, primary sclerosing cholangitis (PSC). Evogliptin is an orally bioavailable, selective dipeptidyl peptidase-4 (DPP-4; CD26 antigen) inhibitor. DPP-4 inhibitors control glucose levels by preventing the breakdown of the incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), which stimulate insulin secretion. For more information, visit the company's website at

Tonix Pharmaceuticals Holding Corp. (TNXP)

Tonix Pharmaceuticals Holding (NASDAQ: TNXP) is biopharmaceutical company developing next-generation therapies for disorders of the central nervous system, including fibromyalgia and post-traumatic stress disorder (PTSD). The company's flagship product candidate, TNX-102 SL, is a fibromyalgia-targeted sublingual tablet containing low-dose cyclobenzaprine HCl. The product is being evaluated in a 500-patient phase 3 AFFIRM study with results expected in the third quarter of 2016. The U.S. Food and Drug Administration has conditionally accepted the proposed trade name Tonmya™ for TNX-102 SL (cyclobenzaprine HCl sublingual tablets), 2.8 mg. For more information, visit the company's website at

Top Image Systems Ltd. (TISA)

Top Image Systems (NASDAQ: TISA) is an innovative provider of enterprise solutions for capturing and validating structured and unstructured content entering organizations from various sources and managing content-driven business processes. The company's solutions automatically capture, process and deliver content across enterprise applications. TISA's flagship eFLOW platform and diverse business process and mobile image processing solutions are marketed in more than 40 countries through a multi-tier network of distributors. For more information, visit the company's website at

Transgene SA (TRGNF)

Transgene SA (OTC: TRGNF) is a European biopharmaceutical company focused on developing targeted immunotherapies for the treatment of infectious diseases and various forms of cancer. The company's programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells. Transgene has two lead clinical-stage programs: TG4010 for non-small cell lung cancer and Pexa-Vec for liver cancer. The company has main headquarters in Strasbourg, France, with additional satellite offices in China and the U.S. For more information, visit the company's website at

TransGlobe Energy Corp. (TGA)

TransGlobe Energy (NASDAQ: TGA) is a Canadian-based, oil exploration and production company with activity mainly focused on the Egypt area. The company holds interests in various production sharing concessions (PSC) in Eastern Desert Egypt and Western Desert Egypt. Its blocks in Eastern Desert Egypt include West Gharib, which covers approximately 34,860 acres; West Bakr, covering over 11,600 acres; North West (NW) Gharib, covering approximately 162,000 acres; South East (SE) Gharib, which covers over 125,650 acres, and South West (SW) Gharib, covering approximately 48,310 acres. For more information, visit the company's website at

TxCell S.A. (TXCLF)

TxCell (OTC: TXCLF) is a France-based biotech focused on developing leading therapies for the treatment of autoimmune diseases. The company also conducts advanced research in studying solutions for anti-inflammatory immunotherapy. TxCell's technology is based on Tr1 T-regulatory cells which enable the regulation of the immune system, aiming to re-establish immunologic equilibrium by bringing regulatory T cells to the body. The company's leading products are used to treat Inflammatory bowel disease, treatment resistant Crohns disease (OvaSave), inflammatory joint diseases, treatment resistant rheumatoid arthritis (TX-RAD) and neurological diseases. For more information, visit the company's website at

Uni-Pixel, Inc. (UNXL)

Uni-Pixel (NASDAQ: UNXL) is an award-winning technology company that develops and markets performance engineered films for the touch screen and flexible electronics markets. The company markets its technologies for touch panel sensor, cover glass replacement, and protective cover film applications under the XTouch™ and Diamond Guard™ brands. For more information, visit the company's website at

uniQure N.V. (QURE)

uniQure N.V. (NASDAQ: QURE) is a biopharmaceutical company focused on finding innovative solutions in the field of gene therapy by directing the expression of a therapeutic protein or restoring the expression of a missing protein through a single therapeutic administration. The company is developing a pipeline of adeno-associated virus (AAV)-based gene therapies using its innovative modular technology platform. uniQure is currently advancing a broad pipeline of innovative gene therapies, initially focused on treatments for rare diseases and cardiovascular ailments. For more information, visit the company's website at

UQM Technologies, Inc. (UQM)

UQM Technologies (NYSE: UQM), established in 1967, has been working for decades manufacturing products toward a cleaner environment. The company's principal products include propulsion motors and generators with power ratings from 50 kilowatts to 250 kilowatts, auxiliary motors and electronic controls and direct current (DC)-to-DC converters. UQM has developed two basic frame size propulsion systems: the PowerPhase Pro for passenger car, light commercial applications, and the PowerPhase HD lineup of products for heavier commercial bus and truck applications and heavier duty marine and other applications. For more information, visit the company's website at

Uranium Energy Corp. (UEC)

Uranium Energy (NYSE: UEC) is a U.S.-based uranium mining and exploration company that currently controls one of the largest databases of historic uranium exploration and development in the area. The company's Hobson processing facility is central to all of its projects in South Texas, including the Palangana in-situ recovery mine and the Goliad in-situ recovery project which is fully permitted for production and under construction. For more information, visit the company's website at

UR-Energy, Inc. (URG)

UR-Energy (NYSE: URG) is a new U.S. mining company operating the Lost Creek in-situ recovery (ISR) uranium facility in south-central Wyoming. The company's Lost Creek processing facility has a 2 million pounds per year physical design capacity. Shirley Basin, its newest project, is one of the Pathfinder Mines assets recently acquired. For more information, visit the company's website at

Valeritas, Inc. (VLRX)

Valeritas (OTC: VLRX) is a commercial-stage medical technology company focused on developing innovative solutions for treating Type 2 diabetes. The company's flagship product, V-Go® Disposable Insulin Delivery device, is a wearable insulin device that enables patients to closely mimic the body's normal physiologic pattern of insulin delivery. The company also has two next generation single-use disposable V-Go devices: V-Go PreFill™ and V-Go Link™. For more information, visit the company's website at

Valneva SE Paris (VNVLF)

Valneva SE Paris (OTC: VNVLF) is a fully integrated medical research company specializing in the manufacturing of groundbreaking vaccine solutions for the treatment of various infectious diseases. The company's portfolio includes two vaccines for travelers: one for the prevention of Japanese encephalitis (IXIARO) and one (DUKORAL) for the prevention of cholera and diarrhea caused by ETEC. For more information, visit the company's website at

VBI Vaccines, Inc. (VBIV)

VBI Vaccines (NASDAQ: VBIV) is a biopharmaceutical company developing and marketing a new generation of vaccines addressing various infectious diseases and immune-oncology. The company's first marketed product is Sci-B-Vac™, a hepatitis B ("HBV") vaccine that mimics all three viral surface antigens of the hepatitis B virus, Sci-B-Vacis . VBI's eVLP Platform technology allows the development of enveloped ("e") virus-like particle ("VLP") vaccines that closely mimic the target virus to elicit a potent immune response. VBI is advancing a pipeline of eVLP vaccines, with lead programs in cytomegalovirus ("CMV") and glioblastoma multiforme ("GBM"). For more information, visit the company's website at

VBL Therapeutics (VBLT)

VBL Therapeutics (NASDAQ: VBLT) is a biopharmaceutical company developing first-class treatments for various cancer indications. The company's clinical pipeline is based on two distinct, proprietary platform technologies that leverage the body's natural physiologic and genetic regulatory elements. To date, VBL has developed two programs based on these platforms – an oncology program and an anti-inflammatory program. VBL's flagship clinical stage product is VB-111, a targeted anti-cancer gene-therapy agent that is positioned to treat a wide range of solid tumors. For more information, visit the company's website at

Verastem, Inc. (VSTM)

Verastem (OTC: VSTM) is a biopharmaceutical company dedicated to discovering and developing drugs to improve outcomes for patients with various cancer indications. The company's product candidates utilize a multi-faceted approach to treat cancer by reducing cancer stem cells, enhancing anti-tumor immunity, and modulating the local tumor microenvironment. Its most advanced clinical product candidates are the Focal Adhesion Kinase inhibitors, VS-6063 and VS-4718, and the dual PI3K/mTOR inhibitor, VS-5584. For more information, visit the company's website at

Vical, Inc. (VICL)

Vical (NASDAQ: VICL) is a biopharmaceutical company focused on the development of therapies for various infectious diseases. The company is using its patented DNA delivery technology and various other therapeutic approaches to prevent and treat chronic or life-threatening developments in various infectious diseases. Vical's proprietary core technology is based on plasmid DNA (pDNA), closed loops of DNA that encode any protein of interest. For more information, visit the company's website at

ViewRay, Inc. (VRAY)

ViewRay (NASDAQ: VRAY) is a medical research company that designs, manufactures and markets the MRIdian® radiation therapy system to address the key limitations of existing external-beam radiation therapy technologies. MRIdian employs MRI-based technology to provide real-time imaging that defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment. The company holds the exclusive worldwide license for its combination of MRI and radiation therapy technologies. For more information, visit the company's website at

Viking Therapeutics, Inc. (VKTX)

Viking Therapeutics (NASDAQ: VKTX) is a clinical-stage biopharmaceutical company focused on the development of therapies for metabolic and endocrine disorders. The company has a portfolio that includes five therapeutic programs either in clinical trials or preclinical studies. Viking's lead clinical program, SARM Therapy, is being developed for the treatment of patients recovering from non-elective hip fracture surgery. It is currently entering phase 2 of trials and has shown results of improving lean body mass in the first 21 days following surgery. For more information, visit the company's website at

Viveve Medical, Inc. (VIVMF)

Viveve Medical (NASDAQ: VIVE) is a women's sexual health company based in California. The company is focused on the commercialization of a revolutionary, non-surgical, non-ablative medical device that remodels collagen and restores vaginal tissue. Viveve treats the condition of vaginal laxity, which results from over stretching the vaginal introital (opening) tissue during childbirth. The Viveve System uses patented, radio frequency (RF) technology to tighten the tissues around the vaginal introitus or opening. Given the non-surgical nature of the treatment, patients experience minimal post-treatment restrictions and recovery times. For more information, visit the company's website at

VolitionRX Ltd. (VNRX)

VolitionRX (NYSE: VNRX) is a life sciences company focused on developing diagnostic tests for cancer and other life-threatening conditions. The company's novel tests are based on the science of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid. VolitionRx's research and development activities are currently centered in Belgium as the company focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and worldwide. For more information, visit the company's website at

Voyager Therapeutics, Inc. (VYGR)

Voyager Therapeutics (NASDAQ: VYGR) is a medical research company committed to advancing the field of AAV gene therapy by innovating and investing in areas such as vector optimization and engineering, dosing techniques, as well as process development and production. The company's pipeline includes VY-AADC01 for Parkinson's disease, which is in an ongoing phase 1b study, as well as preclinical programs VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis (ALS), VY-FXN01 for Friedreich's ataxia, VY-HTT01 for Huntington's disease, VY-SMN101 for spinal muscular atrophy (SMA), VY-TAU01 for frontotemporal dementia and Alzheimer's disease and VY-NAV01 for severe, chronic pain. For more information, visit the company's website at

vTv Therapeutics, Inc. (VTVT)

vTv Therapeutics (NASDAQ: VTVT) is a clinical-stage pharmaceutical company focused on the discovery and development of human therapeutics for various metabolic system and nervous system diseases. The company has a pipeline of small molecule clinical and pre-clinical drug candidates for the treatment of a wide range of human diseases including central nervous system disorders, metabolic disorders, inflammation and cancer. vTv has built its product candidate portfolio through internal discovery and is advancing its product candidates through in-house research and development efforts. For more information, visit the company's website at

Vuzix Corp. (VUZI)

Vuzix (NASDAQ: VUZI) focuses on supplying supplier of Smart-Glasses, Augmented Reality (AR) and Virtual Reality (VR) technologies and products for the consumer and enterprise markets. The company's products include personal display and wearable computing devices that offer users a portable high quality viewing experience, provide solutions for mobility, wearable displays, and virtual and augmented reality. Vuzix holds 43 patents and 23 additional patents pending and numerous IP licenses in the video eyewear field. For more information, visit the company' website at

Western Copper and Gold Corp. (WRN)

Western Copper and Gold (NYSE: WRN) holds significant gold, copper and molybdenum resources and reserves in its Casino Project located in the Yukon, Canada. Casino contains 8.9 million ounces of gold, 4.5 billion pounds of copper, 483 million pounds of molybdenum and 65 million ounces of silver in proven & probable reserves. The company is committed to advancing the Casino project while operating in an environmentally responsible manner. For more information, visit the company's website at

Westport Fuel Systems, Inc. (WPRT)

Westport Fuel Systems (NASDAQ: WPRT) is focused on engineering, manufacturing and supplying the world's most advanced alternative fuel systems and components. The company's aim is to fundamentally change the way the world travels the roads, rails and seas. Its innovative and cost-effective solutions maintain performance while improving efficiency and reducing emissions. Offering a variety of leading brands for transportation and industrial applications, Westport Fuel Systems currently has a global reach, serving customers in over 70 countries, including some of the world's largest and fastest growing markets. For more information, visit the company's website at

Windtree Therapeutics, Inc. (WINT)

Windtree Therapeutics (NASDAQ: WINT) is a biotech company developing groundbreaking KL4 surfactant therapies for respiratory diseases and other potential applications. Its proprietary technology platform includes a synthetic, peptide-containing surfactant (KL4 surfactant) that is structurally similar to human pulmonary surfactant, and novel drug-delivery technologies that are being developed to enable noninvasive administration of aerosolized KL4 surfactant. The company is focused on improving the management of RDS in premature infants and has received orphan drug designation in both the U.S. and E.U. for this indication. For more information, visit the company's website at

XBiotech USA, Inc. (XBIT)

XBiotech USA (NASDAQ: XBIT) is a global biosciences company pioneering the development of therapeutic antibodies based on its True Human™ proprietary technology. The company's broad pipeline of True Human™ antibodies are able to potentially deliver unmatched safety and efficacy because they are cloned directly from individual donors who possess natural immunity against certain targeted diseases. Flagship product Xilonix™ is a potential breakthrough antibody therapy for patients with advanced colorectal cancer. For more information, visit the company's website at

XTL Biopharmaceuticals Ltd. (XTLB)

XTL Biopharmaceuticals (NASDAQ: XTLB) is a biopharmaceutical company that focuses on the development of proprietary products and late-stage pharmaceutical product candidates for the treatment of unmet clinical needs. The company currently has two leading candidates in clinical development: a hCDR1 peptide, a novel compound for the treatment of Systemic Lupus Erythematosus ("SLE"); and rHuEPO, a compound meant for the prolongation of multiple myeloma (MM) advanced-stage patients' survival and improvement of their quality of life. For more information, visit the company's website at

Zynerba Pharmaceuticals, Inc. (ZYNE)

Zynerba Pharmaceuticals (NASDAQ: ZYNE) is a next-generation medical technology company developing synthetic cannabinoid therapeutics for transdermal delivery for patients with high unmet medical needs. The company is targeting severe health conditions including epilepsy, Fragile X syndrome, osteoarthritis, fibromyalgia and peripheral neuropathic pain. Its development pipeline includes patent-protected synthetic transdermal cannabinoid products. ZYN002 is the first and only synthetic CBD formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system. ZYN002 is in phase 2 clinical development in patients with refractory epilepsy. For more information, visit the company's website at


Learn How to Become a Client-Partner

We have a full suite of powerful communications tools as well as an expansive network of more than 5,000 key distribution points. Interested in putting it all to work for you? Leveraging a professional team of journalists and writers, NNW can introduce you to a wide audience of investors, consumers, journalists and the general public.

If would like to work with us, visit our Become a Client-Partner page.


Contact us: 212.418.1217